Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2006 5
2007 7
2008 7
2009 7
2010 8
2011 6
2012 9
2013 10
2014 14
2015 8
2016 10
2017 2
2018 12
2019 16
2020 10
2021 8
2022 13
2023 9
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

134 results

Results by year

Filters applied: . Clear all
Page 1
To be or not to be: the role of CD56 in multiple myeloma.
Cottini F, Benson D. Cottini F, et al. Among authors: benson d. Oncotarget. 2023 Jan 26;14:47-49. doi: 10.18632/oncotarget.28350. Oncotarget. 2023. PMID: 36702332 Free PMC article. No abstract available.
Checkpoint inhibition in myeloma.
Benson DM Jr. Benson DM Jr. Hematology Am Soc Hematol Educ Program. 2016 Dec 2;2016(1):528-533. doi: 10.1182/asheducation-2016.1.528. Hematology Am Soc Hematol Educ Program. 2016. PMID: 27913525 Free PMC article. Review.
Killer immunoglobulin-like receptors and tumor immunity.
Benson DM Jr, Caligiuri MA. Benson DM Jr, et al. Cancer Immunol Res. 2014 Feb;2(2):99-104. doi: 10.1158/2326-6066.CIR-13-0219. Cancer Immunol Res. 2014. PMID: 24592397 Free PMC article. Review.
Retraction Notice to: Downregulation of p53-inducible microRNAs 192, 194, and 215 Impairs the p53/MDM2 Autoregulatory Loop in Multiple Myeloma Development.
Pichiorri F, Suh SS, Rocci A, De Luca L, Taccioli C, Santhanam R, Zhou W, Benson DM, Hofmainster C, Alder H, Garofalo M, Di Leva G, Volinia S, Lin HJ, Perrotti D, Kuehl M, Aqeilan RI, Palumbo A, Croce CM. Pichiorri F, et al. Among authors: benson dm. Cancer Cell. 2022 Nov 14;40(11):1441. doi: 10.1016/j.ccell.2022.10.006. Epub 2022 Oct 27. Cancer Cell. 2022. PMID: 36306793 Free PMC article. No abstract available.
Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial.
Dimopoulos MA, Richardson PG, Bahlis NJ, Grosicki S, Cavo M, Beksaç M, Legieć W, Liberati AM, Goldschmidt H, Belch A, Magen H, Larocca A, Laubach JP, Petrucci MT, Reece D, White D, Mateos MV, Špička I, Lazaroiu M, Berdeja J, Kaufman JL, Jou YM, Ganetsky A, Popa McKiver M, Lonial S, Weisel K; ELOQUENT-1 investigators. Dimopoulos MA, et al. Lancet Haematol. 2022 Jun;9(6):e403-e414. doi: 10.1016/S2352-3026(22)00103-X. Epub 2022 May 9. Lancet Haematol. 2022. PMID: 35550060 Clinical Trial.
CD56 expression predicts response to Daratumumab-based regimens.
Robinette AJ, Huric L, Dona K, Benson D, Cottini F. Robinette AJ, et al. Among authors: benson d. Blood Cancer J. 2024 Apr 12;14(1):62. doi: 10.1038/s41408-024-01051-5. Blood Cancer J. 2024. PMID: 38609355 Free PMC article. No abstract available.
134 results